Literature DB >> 22650795

Radioligand dissociation measurements: potential interference of rebinding and allosteric mechanisms and physiological relevance of the biological model systems.

Georges Vauquelin1, Isabelle Van Liefde.   

Abstract

INTRODUCTION: In many situations, optimal drug therapy requires continuing high levels of target occupancy and this notion has led pharmacologists to focus their attention on the rate by which drug candidates dissociate from their target. To this end, radioligand dissociation experiments are often carried out on in vitro models, such as intact cells and the membranes thereof, but the interpretation of the collected data is sometimes ambiguous. AREAS COVERED: Pharmacodynamics is concerned about what the drug does to the target and, in this respect, allosteric modulation constitutes a quite novel, very promising research topic. The ability of unlabeled drugs to accelerate radioligand dissociation is often advocated to be a hallmark of such mechanism. Yet, the present computerized simulations reveal that competitive drugs produce the same effect by preventing hindered diffusion- and "forced proximity"-related rebinding of the radioligand. Herein, the authors provide hints to discern among those mechanisms. EXPERT OPINION: A critical, but constructive appraisal of radioligand dissociation binding data leads to the viewpoint that, from a physiological perspective, dissociation from confluent target-expressing plated cells, when in a naïve medium, is likely to provide the most pertinent insight in that ligand's in vivo residence time.

Mesh:

Substances:

Year:  2012        PMID: 22650795     DOI: 10.1517/17460441.2012.687720

Source DB:  PubMed          Journal:  Expert Opin Drug Discov        ISSN: 1746-0441            Impact factor:   6.098


  9 in total

Review 1.  On the different experimental manifestations of two-state 'induced-fit' binding of drugs to their cellular targets.

Authors:  Georges Vauquelin; Isabelle Van Liefde; David C Swinney
Journal:  Br J Pharmacol       Date:  2016-03-15       Impact factor: 8.739

2.  Simplified models for heterobivalent ligand binding: when are they applicable and which are the factors that affect their target residence time.

Authors:  Georges Vauquelin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-06-28       Impact factor: 3.000

3.  'Partial' competition of heterobivalent ligand binding may be mistaken for allosteric interactions: a comparison of different target interaction models.

Authors:  Georges Vauquelin; David Hall; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2015-03-17       Impact factor: 8.739

4.  Effects of target binding kinetics on in vivo drug efficacy: koff , kon and rebinding.

Authors:  Georges Vauquelin
Journal:  Br J Pharmacol       Date:  2016-07-04       Impact factor: 8.739

Review 5.  Cell membranes… and how long drugs may exert beneficial pharmacological activity in vivo.

Authors:  Georges Vauquelin
Journal:  Br J Clin Pharmacol       Date:  2016-05-29       Impact factor: 4.335

6.  A [(32)P]NAD(+)-based method to identify and quantitate long residence time enoyl-acyl carrier protein reductase inhibitors.

Authors:  Weixuan Yu; Carla Neckles; Andrew Chang; Gopal Reddy Bommineni; Lauren Spagnuolo; Zhuo Zhang; Nina Liu; Christina Lai; James Truglio; Peter J Tonge
Journal:  Anal Biochem       Date:  2015-02-14       Impact factor: 3.365

7.  A general mechanism for competitor-induced dissociation of molecular complexes.

Authors:  Thayaparan Paramanathan; Daniel Reeves; Larry J Friedman; Jane Kondev; Jeff Gelles
Journal:  Nat Commun       Date:  2014-10-24       Impact factor: 14.919

Review 8.  Binding kinetics of ligands acting at GPCRs.

Authors:  David A Sykes; Leigh A Stoddart; Laura E Kilpatrick; Stephen J Hill
Journal:  Mol Cell Endocrinol       Date:  2019-02-08       Impact factor: 4.102

9.  Probe dependency in the determination of ligand binding kinetics at a prototypical G protein-coupled receptor.

Authors:  Reggie Bosma; Leigh A Stoddart; Victoria Georgi; Monica Bouzo-Lorenzo; Nick Bushby; Loretta Inkoom; Michael J Waring; Stephen J Briddon; Henry F Vischer; Robert J Sheppard; Amaury Fernández-Montalván; Stephen J Hill; Rob Leurs
Journal:  Sci Rep       Date:  2019-05-27       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.